Think of it as radical bio-intelligence

We combine artificial intelligence with automation to conduct experimental biology at scale — testing thousands of compounds on hundreds of cellular disease models in parallel. Our embrace of systems biology and our commitment to an unbiased approach are leading to novel discoveries. With every experiment, our system gets smarter.

Watch the video

We’re aiming for 100 new treatments by 2025

We know this sounds improbable, but we wanted ambitious goals to stretch ourselves further, force ourselves to question assumptions, and move faster. The results in our pipeline indicate we are onto something. Look at the data with us.

“Deep learning has recently proven capable of driving cars, beating the world champion of the game of Go, translating from one language to another and recognizing faces dramatically better than any previous efforts to date. Recursion is taking this success and applying it to millions of high-resolution cellular images, with a high potential to make biological discoveries with a medical impact and breadth never seen before.”

Yoshua Bengio,
Recursion Scientific Advisor

Our investors

The latest news

Articles and Press Releases
stdClass Object ( [limit] => 3 [order_by] => publish_date [order] => desc [post_types] => Array ( [0] => press-article [1] => press-release ) [template] => press_release [filter_by] => [acf_field] => Array ( ) [tax] => Array ( ) [acf] => )
Blog and Publications
stdClass Object ( [limit] => 3 [order_by] => publish_date [order] => desc [post_types] => Array ( [0] => post ) [template] => blog [filter_by] => [acf_field] => Array ( ) [tax] => Array ( ) [acf] => )
AI-Enabled Phenotypic Screens Reveal Clinically Relevant Drugs
by Recursion Pharmaceuticals
Biology
Cell Painting, a high-content image-based assay for morphological profiling using multiplexed fluorescent dyes
by Christopher C. Gibson
Biology
Strategy for Identifying Repurposed Drugs for the Treatment of Cerebral Cavernous Malformation
by Christopher C. Gibson
Biology